Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
==== 1952–53 ==== When he joined the Cardinals, broadcaster Harry Caray started calling him "Vinegar Bend," and the nickname stuck. He was hailed as "the left-handed Dizzy Dean" by sportswriter Red Smith, which Mizell called "a perty heavy load for a boy to tote." Added to St. Louis's starting rotation for the 1952 campaign, Mizell made his major league debut on April 22 against the Cincinnati Reds. He gave up two runs in the first inning, then held the Reds scoreless for the rest of the game, though he took the loss in a 2–1 defeat. Two starts later, on May 2, he limited the Philadelphia Phillies to four hits and two runs in a complete game, winning in the ninth when Peanuts Lowrey broke a 2–2 tie with an RBI-single. After that win, he lost three games in a row, then received four consecutive no decisions. He ended the winless streak on June 21, when he struck out 11 in his first major league shutout against the Boston Braves. That started a streak of six decisions won in a row, during which time Mizell posted a 3.05 ERA. He would not lose again until August 27. On September 5, he threw his second shutout of the year, tying his season high with 11 strikeouts in a 4–0 victory over the Pittsburgh Pirates. Mizell finished his rookie season with a 10–8 record and a 3.65 ERA in 30 starts. He led the National League (NL) in strikeouts per 9 innings pitched with a 6.9 mark, and his 146 strikeouts ranked fourth in the league (behind Warren Spahn's 183, Bob Rush's 157, and Robin Roberts's 148). However, he also led the league in walks (103, tied with Herm Wehmeier).
sense A distinction made between the individual strands of a double-stranded DNA molecule in order to easily and specifically identify each strand. The two complementary strands are distinguished as sense and antisense or, equivalently, the coding strand and the template strand. It is the antisense/template strand which is actually used as the template for transcription; the sense/coding strand merely resembles the sequence of codons on the RNA transcript, which makes it possible to determine from the DNA sequence alone the expected amino acid sequence of any protein translated from the RNA transcript. Which strand is which is relative only to a particular RNA transcript and not to the entire DNA molecule; that is, either strand can function as the sense/coding or antisense/template strand.
Single-walled carbon nanotubes (SWCNTs) have diameters around 0.5–2.0 nanometres, about a 100,000th the width of a human hair. They can be idealised as cutouts from a two-dimensional graphene sheet rolled up to form a hollow cylinder. Multi-walled carbon nanotubes (MWCNTs) consist of nested single-wall carbon nanotubes in a nested, tube-in-tube structure. Double- and triple-walled carbon nanotubes are special cases of MWCNT. Carbon nanotubes can exhibit remarkable properties, such as exceptional tensile strength and thermal conductivity because of their nanostructure and strength of the bonds between carbon atoms. Some SWCNT structures exhibit high electrical conductivity while others are semiconductors. In addition, carbon nanotubes can be chemically modified. These properties are expected to be valuable in many areas of technology, such as electronics, optics, composite materials (replacing or complementing carbon fibres), nanotechnology (including nanomedicine), and other applications of materials science. The predicted properties for SWCNTs were tantalising, but a path to synthesising them was lacking until 1993, when Iijima and Ichihashi at NEC, and Bethune and colleagues at IBM independently discovered that co-vaporising carbon and transition metals such as iron and cobalt could specifically catalyse SWCNT formation. These discoveries triggered research that succeeded in greatly increasing the efficiency of the catalytic production technique, and led to an explosion of work to characterise and find applications for SWCNTs.
== Ribozymes == At the time of the hypercycle theory formulation, ribozymes were not known. After the breakthrough of discovering RNA's catalytic properties in 1982, it was realized that RNA had the ability to integrate protein and nucleotide-chain properties into one entity. Ribozymes potentially serving as templates and catalysers of replication can be considered components of quasispecies that can self-organize into a hypercycle without the need to invent a translation process. In 2001, a partial RNA polymerase ribozyme was designed via directed evolution. Nevertheless, it was able to catalyse only a polymerization of a chain having the size of about 14 nucleotides, even though it was 200 nucleotides long. The most up-to-date version of this polymerase was shown in 2013. While it has an ability to catalyse polymerization of longer sequences, even of its own length, it cannot replicate itself due to a lack of sequence generality and its inability to transverse secondary structures of long RNA templates. However, it was recently shown that those limitations could in principle be overcome by the assembly of active polymerase ribozymes from several short RNA strands. In 2014, a cross-chiral RNA polymerase ribozyme was demonstrated. It was hypothesized that it offers a new mode of recognition between an enzyme and substrates, which is based on the shape of the substrate, and allows avoiding the Watson-Crick pairing and, therefore, may provide greater sequence generality.
Sources: en.wikipedia.org
=== Disadvantage === As some proteins require chaperonin for proper folding, Komagataella is unable to produce a number of proteins, since it does not contain the appropriate chaperones. The technologies of introducing genes of mammalian chaperonins into the yeast genome and overexpressing existing chaperonins still require improvement.
When lipids are extracted or isolated from biomembranes, polymorphism and mesomorphism can occur because they are then no longer under the intermolecular constraints that are present within the biomembrane. This can lead to formation of non-lamellar (non-bilayer) or lamellar phases in phospholipids. "Polymorphism" refers to formation of diverse structures such as three-dimensional tubes, rods, and structures with cubic symmetry. Mesomorphism refers to phase transitions when heat is applied. For example, a lipid can be in the lamellar phase at a lower temperature, but as the temperature increases, it transitions into a non-lamellar phase. It is important to consider the size of the hydrophilic region versus the hydrophobic region. For example, if the hydrophilic region and hydrophobic region are similar, a cylindrical shape lipid bilayer is formed; but when the hydrophilic regions is smaller than the hydrophobic region a cone-shaped lipid bilayer is formed. Another example is the formation of micelles which has a non-lamellar formation in which the hydrophilic region is significantly larger compared to the hydrophobic region. There are various liquid-crystalline phases that can exist in lipids. Liquid-crystalline phases are when the hydrophobic chain regions are not motionless but are allowed to move about freely in a fluid-like melted state. The lamellar phase (Lα) is the most common and dominant phase in lipids and are aligned as stacks of bilayers on top of bilayers oriented in one single direction.
==== Physiological effects ==== Angiotensin II exhibits endocrine, autocrine/paracrine, and intracrine functions. It promotes aldosterone release from the adrenal cortex, as well as arginine vasopressin release from the posterior pituitary. It acts directly upon the proximal tubules of the kidney to regulate water and Na+ reabsorption, promoting reabsorption at very low concentrations while increasingly inhibiting reabsorption with increasing concentrations. In the proximal tubule, it promotes Na+ reabsorption and H+ excretion (which is coupled to bicarbonate reabsorption) by the Na+/H+ exchanger. It causes venous and arterial vasoconstriction by a Gq alpha subunit-coupled receptor upon vascular smooth muscle cells (with downstream IP3-dependent mechanism causing a rise in intracellular Ca2+ to effect smooth muscle excitation-contraction coupling), thus acting to increase blood pressure.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.